Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: From a prospective randomized trial

International Angiology

Volumn 34, Issue 5, 2015, Pages 428-436

  Rabe, E ^a   Agus, G B ^b   Roztocil, K ^c  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF MILAN   (Italy)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Quality of life; Venous insufficiency; Visual Analog Scale

Indexed keywords

DAFLON; PLACEBO; WATER; FLAVONOID;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CATARACT; CHRONIC VENOUS DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; DRUG TOLERANCE; ERYSIPELAS; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; HYPERTENSIVE CRISIS; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; PARALLEL DESIGN; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VEIN DISEASE; VEIN PAIN; VISUAL ANALOG SCALE; VOLUMETRY; WATER DISPLACEMENT VOLUMETRY; ADOLESCENT; CHRONIC DISEASE; CLINICAL TRIAL; LEG; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PATHOPHYSIOLOGY; VENOUS INSUFFICIENCY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; FLAVONOIDS; HUMANS; LEG; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUALITY OF LIFE; VENOUS INSUFFICIENCY; YOUNG ADULT;

EID: 84946900108     PISSN: 03929590     EISSN: 18271839     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pannier-Fischer F, Rabe E. [Epidemiology of chronic venous diseases]. Hautarzt 2003;54:1037-44.
2. Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med 2006;355:488-98.
3. Rabe E, Pannier F. What have we learned from the Bonn Vein Study? Phlebolymphology 2006;13:186-91.
4. Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg 2011;41:117-25.
5. Eklöf B, Perrin M, Delis KT, Rutherford RB, Gloviczki P. Updated terminology of chronic venous disorders: the VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg 2009;49:498-501.
6. Allaert FA, Causse C. Pharmaco-epidemiology of the treatment of chronic venous insufficiency in general medicine. Int Angiol 2002;21:12-7.
7. Kahn SR, M'Lan CE, Lamping DL, Kurz X, Bérard A, Abenhaim LA. VEINES Study Group. Relationship between clinical classification of chronic venous disease and patient-reported quality of life: results from an international cohort study. J Vasc Surg 2004;39:823-8.
8. Barbe R, Amiel M. Pharmacodynamic properties and therapeutic efficacy of Daflon 500 mg. Phlebology 1992; (Suppl 2):41-4.
9. Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol 1993;12:69-72.
10. Gilly R, Pillion G, Frileux C. Evaluation of a new venoactive micronized flavonoid fraction (S 5682) symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology 1994;9:67-70.
11. Vayssairat M, Maurel A, Gouny P, Baudot N, Gaitz JP, Nussaume O. Leg volumetry: an accurate method for chronic venous insufficiency quantification. J Mal Vasc 1994;19:108-10.
12. Launois R, Reboul-Marty J, Henry B. Construction and validation of a quality of life questionnaire in chronic lower limb venous insufficiency (CIVIQ). Qual Life Res 1996;5:539-54.
13. Jantet G. RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids. Angiology 2000;51:31-7
14. Vayssairat M, Maurel A, Gouny P, Baudot N, Gaitz JP, Nussaume O. La volumétrie: une méthode précise de quantification en phlébologie. J Mal Vasc 1994;19:108-10.
15. Committee for medicinal products for human use. Guideline on clinical medicinal productintended for the treatment of neuropathic pain. [CPMP/EWP/2 52/03 Rev. 1]. 24-1-2007. European Medicines Agency.
16. Committee for medicinal products for human use. Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. [CPMP/EWP/784/97 Rev. 1]. 20-1-2010. European Medicines Agency.
17. Chassignolle JF, Amiel M, Lanfranchi G. Activité thérapeutique de Daflon 500 mg dans l'insuffisance veineuse fonctionnelle. JIM 1987;99:32-35.
18. Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology 2002;53:245-56.
19. Ramelet AA, Boisseau MR, Allegra C, Nicolaides A, Jaeger K, Carpentier P et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc 2005;33:309-19.
20. Rabe E, Stucker M, Ottillinger B. Water displacement leg volumetry in clinical studies - A discussion of error sources. BMC Med Res Methodol 2010;10:5-13.
21. Vanscheidt W, Heidrich H, Junger M, Rabe E. Guidelines for testing drugs for chronic venous insufficiency. Vasa 2000;29:274-8.